guest ::
| Home > Articles > Published articles > Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation : |
| Home > Articles > Published articles > Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation : |
(Program for Comparative Effectiveness Research. Morsani College of Medicine. University of South Florida) (Department of Adult Hematology and Stem Cell Transplantation. King Faisal Specialist Hospital and Research Centre) (Moffitt Cancer Center (Tampa, Estats Units d'Amèrica)) (Memorial Sloan Kettering Cancer Center. Department of Pediatrics) (Massachusetts General Hospital (Boston)) (Vanderbilt University Medical Center) (Thomas Jefferson University Hospital) (Sheikh Shakhbout Medical City Abu Dhabi) (National Cancer Center Hospital) (University of Texas Southwestern Medical Center) (Sorbonne Université. INSERM. Centre de Recherche Saint-Antoine and Hôpital Saint-Antoine. Service d'Hématologie Clinique et Thérapie Cellulaire) (Oregon Health & Science University) (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) (The Ohio State University. Division of Hematology) (Institut d'Investigació Biomèdica Sant Pau) (Vanderbilt University Medical Center) (Medical College of Wisconsin)| Date: | 2021 |
| Abstract: | Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for certain hematologic malignancies and nonmalignant diseases. The field of allo-HCT has witnessed significant advances, including broadening indications for transplantation, availability of alternative donor sources, less toxic preparative regimens, new cell manipulation techniques, and novel GVHD prevention methods, all of which have expanded the applicability of the procedure. These advances have led to clinical practice conundrums when applying traditional definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism, because these may vary based on donor type, cell source, cell dose, primary disease, graft-versus-host disease (GVHD) prophylaxis, and conditioning intensity, among other variables. To address these contemporary challenges, we surveyed a panel of allo-HCT experts in an attempt to standardize these definitions. We analyzed survey responses from adult and pediatric transplantation physicians separately. Consensus was achieved for definitions of neutrophil and platelet recovery, graft rejection, graft failure, poor graft function, and donor chimerism, but not for delayed engraftment. Here we highlight the complexities associated with the management of mixed donor chimerism in malignant and nonmalignant hematologic diseases, which remains an area for future research. We recognize that there are multiple other specific, and at times complex, clinical scenarios for which clinical management must be individualized. |
| Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.  |
| Language: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Subject: | Allogeneic hematopoietic cell transplantation ; Hematopoietic recovery ; Graft rejection ; Graft failure ; Donor chimerism |
| Published in: | Transplantation and cellular therapy, Vol. 27 Núm. 8 (august 2021) , p. 642-649, ISSN 2666-6367 |
